MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company is headquartered in Austin, Texas.…
MindWalk Announces Results of 2026 Annual General Meeting of Shareholders
MindWalk Holdings (NASDAQ: HYFT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 74 employees.
The shares were at 0.6844 USD on 20 November 2026, down 61.8% over 52 weeks. Its 52-week range is 0.6400 USD to 2.990 USD: the price is 77.1% below the high and 6.9% above the low.
Its market capitalisation is 32.56M USD.
MindWalk Holdings reports return on equity of -118.7%, an operating margin of -104.2% and revenue up 21.3% year over year.
It holds more cash than debt, a net cash position of 4.14M CAD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 15 December 2026.